CDKN2A and glioblastoma: The prognostic significance of MTAP deletion has not been previously well characterized, but our results suggest that MTAP deletion may potentially serve as a surrogate marker for CDKN2A deletion in prognostic evaluation of IDHwt glioblastoma patients [17].